Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia
Identifieur interne : 001D20 ( Istex/Corpus ); précédent : 001D19; suivant : 001D21Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia
Auteurs : R. Cole ; Hallett ; L. G. CohenSource :
- Movement Disorders [ 0885-3185 ] ; 1995-07.
English descriptors
- KwdEn :
Abstract
Ten patients with focal dystonia of the hand, all of whom had benefited in an open‐label study of botulinum toxin, were treated with botulinum toxin‐A in a double‐blind study. Response was assessed by three measures: (a) subjective rating, provided by patients' reports of the effect of the injections on the dystonia; (b) objective testing, consisting of manual muscle testing (MRC scale) to measure muscle strength in all patients, timing of a writing sample and counting the number of errors of writing off‐the‐line in six patients with writer's cramp, counting the number of errors on a standard test of transcription in two patients with stenographer's cramp, and rating by professional musicians of the performances of two patients with musician's cramp; and (c) physicians'rating, provided by a review of the patients' videotaped performance by neurologists who were unaware of which treatment was administered. Eight of the 10 patients had greater subjective improvement with botulinum toxin than with placebo, and this impression was verified by at least one objective test in six patients. Two patients failed to have a better response to botulinum toxin than to placebo, and their reports were verified by the objective tests. This study confirms the efficacy of botulinum toxin in many patients with focal hand dystonia.
Url:
DOI: 10.1002/mds.870100411
Links to Exploration step
ISTEX:1DAF43098754ACBB8DA132645D8998A5E11D88BELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia</title><author><name sortKey="Cole, R" sort="Cole, R" uniqKey="Cole R" first="R." last="Cole">R. Cole</name><affiliation><mods:affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hallett" sort="Hallett" uniqKey="Hallett" last="Hallett">Hallett</name><affiliation><mods:affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Cohen, L G" sort="Cohen, L G" uniqKey="Cohen L" first="L. G." last="Cohen">L. G. Cohen</name><affiliation><mods:affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1DAF43098754ACBB8DA132645D8998A5E11D88BE</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1002/mds.870100411</idno><idno type="url">https://api.istex.fr/document/1DAF43098754ACBB8DA132645D8998A5E11D88BE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001D20</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia</title><author><name sortKey="Cole, R" sort="Cole, R" uniqKey="Cole R" first="R." last="Cole">R. Cole</name><affiliation><mods:affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Hallett" sort="Hallett" uniqKey="Hallett" last="Hallett">Hallett</name><affiliation><mods:affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Cohen, L G" sort="Cohen, L G" uniqKey="Cohen L" first="L. G." last="Cohen">L. G. Cohen</name><affiliation><mods:affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-07">1995-07</date><biblScope unit="vol">10</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="466">466</biblScope><biblScope unit="page" to="471">471</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1DAF43098754ACBB8DA132645D8998A5E11D88BE</idno><idno type="DOI">10.1002/mds.870100411</idno><idno type="ArticleID">MDS870100411</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Botulinum toxin</term><term>Clinical trial</term><term>Dystonia</term><term>Writer's cramp</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ten patients with focal dystonia of the hand, all of whom had benefited in an open‐label study of botulinum toxin, were treated with botulinum toxin‐A in a double‐blind study. Response was assessed by three measures: (a) subjective rating, provided by patients' reports of the effect of the injections on the dystonia; (b) objective testing, consisting of manual muscle testing (MRC scale) to measure muscle strength in all patients, timing of a writing sample and counting the number of errors of writing off‐the‐line in six patients with writer's cramp, counting the number of errors on a standard test of transcription in two patients with stenographer's cramp, and rating by professional musicians of the performances of two patients with musician's cramp; and (c) physicians'rating, provided by a review of the patients' videotaped performance by neurologists who were unaware of which treatment was administered. Eight of the 10 patients had greater subjective improvement with botulinum toxin than with placebo, and this impression was verified by at least one objective test in six patients. Two patients failed to have a better response to botulinum toxin than to placebo, and their reports were verified by the objective tests. This study confirms the efficacy of botulinum toxin in many patients with focal hand dystonia.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>R. Cole</name><affiliations><json:string>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</json:string></affiliations></json:item><json:item><name>Dr. Hallett</name><affiliations><json:string>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</json:string></affiliations></json:item><json:item><name>L. G. Cohen</name><affiliations><json:string>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Botulinum toxin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Writer's cramp</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Clinical trial</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Ten patients with focal dystonia of the hand, all of whom had benefited in an open‐label study of botulinum toxin, were treated with botulinum toxin‐A in a double‐blind study. Response was assessed by three measures: (a) subjective rating, provided by patients' reports of the effect of the injections on the dystonia; (b) objective testing, consisting of manual muscle testing (MRC scale) to measure muscle strength in all patients, timing of a writing sample and counting the number of errors of writing off‐the‐line in six patients with writer's cramp, counting the number of errors on a standard test of transcription in two patients with stenographer's cramp, and rating by professional musicians of the performances of two patients with musician's cramp; and (c) physicians'rating, provided by a review of the patients' videotaped performance by neurologists who were unaware of which treatment was administered. Eight of the 10 patients had greater subjective improvement with botulinum toxin than with placebo, and this impression was verified by at least one objective test in six patients. Two patients failed to have a better response to botulinum toxin than to placebo, and their reports were verified by the objective tests. This study confirms the efficacy of botulinum toxin in many patients with focal hand dystonia.</abstract><qualityIndicators><score>5.559</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1332</abstractCharCount><pdfWordCount>3063</pdfWordCount><pdfCharCount>18844</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>208</abstractWordCount></qualityIndicators><title>Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia</title><genre><json:string>Serial article</json:string></genre><host><volume>10</volume><pages><total>6</total><last>471</last><first>466</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1002/mds.870100411</json:string></doi><id>1DAF43098754ACBB8DA132645D8998A5E11D88BE</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/1DAF43098754ACBB8DA132645D8998A5E11D88BE/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/1DAF43098754ACBB8DA132645D8998A5E11D88BE/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1DAF43098754ACBB8DA132645D8998A5E11D88BE/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1995</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia</title><author><persName><forename type="first">R.</forename><surname>Cole</surname></persName><affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</affiliation></author><author><persName><surname>Hallett</surname><roleName type="degree">Dr.</roleName></persName><note type="correspondence"><p>Correspondence: Building 10, Room 5N226, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD 20892, U.S.A.</p></note><affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</affiliation></author><author><persName><forename type="first">L. G.</forename><surname>Cohen</surname></persName><affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1995-07"></date><biblScope unit="vol">10</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="466">466</biblScope><biblScope unit="page" to="471">471</biblScope></imprint></monogr><idno type="istex">1DAF43098754ACBB8DA132645D8998A5E11D88BE</idno><idno type="DOI">10.1002/mds.870100411</idno><idno type="ArticleID">MDS870100411</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1995</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Ten patients with focal dystonia of the hand, all of whom had benefited in an open‐label study of botulinum toxin, were treated with botulinum toxin‐A in a double‐blind study. Response was assessed by three measures: (a) subjective rating, provided by patients' reports of the effect of the injections on the dystonia; (b) objective testing, consisting of manual muscle testing (MRC scale) to measure muscle strength in all patients, timing of a writing sample and counting the number of errors of writing off‐the‐line in six patients with writer's cramp, counting the number of errors on a standard test of transcription in two patients with stenographer's cramp, and rating by professional musicians of the performances of two patients with musician's cramp; and (c) physicians'rating, provided by a review of the patients' videotaped performance by neurologists who were unaware of which treatment was administered. Eight of the 10 patients had greater subjective improvement with botulinum toxin than with placebo, and this impression was verified by at least one objective test in six patients. Two patients failed to have a better response to botulinum toxin than to placebo, and their reports were verified by the objective tests. This study confirms the efficacy of botulinum toxin in many patients with focal hand dystonia.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Botulinum toxin</term></item><item><term>Dystonia</term></item><item><term>Writer's cramp</term></item><item><term>Clinical trial</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1994-11-27">Registration</change><change when="1995-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/1DAF43098754ACBB8DA132645D8998A5E11D88BE/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v10:4</doi><numberingGroup><numbering type="journalVolume" number="10">10</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="1995-07">July 1995</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="11" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870100411</doi><idGroup><id type="unit" value="MDS870100411"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1995 Movement Disorder Society</copyright><eventGroup><event type="manuscriptAccepted" date="1994-11-27"></event><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">466</numbering><numbering type="pageLast">471</numbering></numberingGroup><correspondenceTo>Building 10, Room 5N226, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD 20892, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870100411.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="10"></count></countGroup><titleGroup><title type="main" xml:lang="en">Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia</title><title type="short" xml:lang="en">BOTULINUM TOXIN IN FOCAL HAND DYSTONIA</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>R.</givenNames><familyName>Cole</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>M.</givenNames><familyName>Hallett</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>L. G.</givenNames><familyName>Cohen</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Botulinum toxin</keyword><keyword xml:id="kwd2">Dystonia</keyword><keyword xml:id="kwd3">Writer's cramp</keyword><keyword xml:id="kwd4">Clinical trial</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Ten patients with focal dystonia of the hand, all of whom had benefited in an open‐label study of botulinum toxin, were treated with botulinum toxin‐A in a double‐blind study. Response was assessed by three measures: (a) subjective rating, provided by patients' reports of the effect of the injections on the dystonia; (b) objective testing, consisting of manual muscle testing (MRC scale) to measure muscle strength in all patients, timing of a writing sample and counting the number of errors of writing off‐the‐line in six patients with writer's cramp, counting the number of errors on a standard test of transcription in two patients with stenographer's cramp, and rating by professional musicians of the performances of two patients with musician's cramp; and (c) physicians'rating, provided by a review of the patients' videotaped performance by neurologists who were unaware of which treatment was administered. Eight of the 10 patients had greater subjective improvement with botulinum toxin than with placebo, and this impression was verified by at least one objective test in six patients. Two patients failed to have a better response to botulinum toxin than to placebo, and their reports were verified by the objective tests. This study confirms the efficacy of botulinum toxin in many patients with focal hand dystonia.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>BOTULINUM TOXIN IN FOCAL HAND DYSTONIA</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia</title></titleInfo><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Cole</namePart><affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Hallett</namePart><affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</affiliation><description>Correspondence: Building 10, Room 5N226, National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD 20892, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L. G.</namePart><namePart type="family">Cohen</namePart><affiliation>Human Motor Control Section, Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institues of Health, Bethesda, Maryland, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1995-07</dateIssued><dateValid encoding="w3cdtf">1994-11-27</dateValid><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">10</extent></physicalDescription><abstract lang="en">Ten patients with focal dystonia of the hand, all of whom had benefited in an open‐label study of botulinum toxin, were treated with botulinum toxin‐A in a double‐blind study. Response was assessed by three measures: (a) subjective rating, provided by patients' reports of the effect of the injections on the dystonia; (b) objective testing, consisting of manual muscle testing (MRC scale) to measure muscle strength in all patients, timing of a writing sample and counting the number of errors of writing off‐the‐line in six patients with writer's cramp, counting the number of errors on a standard test of transcription in two patients with stenographer's cramp, and rating by professional musicians of the performances of two patients with musician's cramp; and (c) physicians'rating, provided by a review of the patients' videotaped performance by neurologists who were unaware of which treatment was administered. Eight of the 10 patients had greater subjective improvement with botulinum toxin than with placebo, and this impression was verified by at least one objective test in six patients. Two patients failed to have a better response to botulinum toxin than to placebo, and their reports were verified by the objective tests. This study confirms the efficacy of botulinum toxin in many patients with focal hand dystonia.</abstract><subject lang="en"><genre>Keywords</genre><topic>Botulinum toxin</topic><topic>Dystonia</topic><topic>Writer's cramp</topic><topic>Clinical trial</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>466</start><end>471</end><total>6</total></extent></part></relatedItem><identifier type="istex">1DAF43098754ACBB8DA132645D8998A5E11D88BE</identifier><identifier type="DOI">10.1002/mds.870100411</identifier><identifier type="ArticleID">MDS870100411</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1995 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001D20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1DAF43098754ACBB8DA132645D8998A5E11D88BE
|texte= Double‐Blind trial of botulinum toxin for treatment of focal hand dystonia
}}
| This area was generated with Dilib version V0.6.23. |  |